Works matching AU Thuresson, Marcus

Results: 56
    1
    2
    3
    4
    5

    Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2402, doi. 10.1111/dom.15092
    By:
    • Goh, Su‐Yen;
    • Kosiborod, Mikhail N.;
    • Lam, Carolyn S. P.;
    • Cavender, Matthew A.;
    • Kohsaka, Shun;
    • Norhammar, Anna;
    • Birkeland, Kåre I.;
    • Holl, Reinhard W.;
    • Mauricio, Dídac;
    • Tangri, Navdeep;
    • Shaw, Jonathan E.;
    • Thuresson, Marcus;
    • Fenici, Peter;
    • Kim, Dae Jung
    Publication type:
    Article
    6

    Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1277, doi. 10.1111/dom.14698
    By:
    • Norhammar, Anna;
    • Bodegard, Johan;
    • Eriksson, Jan W.;
    • Haller, Hermann;
    • Linssen, Gerard C. M.;
    • Banerjee, Amitava;
    • Karasik, Avraham;
    • Mamouris, Pavlos;
    • Tangri, Navdeep;
    • Taveira‐Gomes, Tiago;
    • Maggioni, Aldo P.;
    • Botana, Manuel;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Yajima, Toshitaka;
    • Kadowaki, Takashi;
    • Birkeland, Kåre I.
    Publication type:
    Article
    7

    Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1431, doi. 10.1111/dom.14356
    By:
    • Lam, Carolyn S. P.;
    • Karasik, Avraham;
    • Melzer‐Cohen, Cheli;
    • Cavender, Matthew A.;
    • Kohsaka, Shun;
    • Norhammar, Anna;
    • Thuresson, Marcus;
    • Chen, Hungta;
    • Wittbrodt, Eric;
    • Fenici, Peter;
    • Kosiborod, Mikhail
    Publication type:
    Article
    8
    9
    10

    Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 75, doi. 10.1111/dom.14189
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Banerjee, Amitava;
    • Kim, Dae Jung;
    • Norhammar, Anna;
    • Eriksson, Jan W.;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Ha, Kyoung Hwa;
    • Kossack, Nils;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    11
    12

    Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1607, doi. 10.1111/dom.14074
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Eriksson, Jan W.;
    • Norhammar, Anna;
    • Haller, Hermann;
    • Linssen, Gerard C.M.;
    • Banerjee, Amitava;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Garal‐Pantaler, Elena;
    • Overbeek, Jetty;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19

    Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
    By:
    • Sonneveld, Pieter;
    • Richardson, Paul G.;
    • Ludwig, Heinz;
    • Dimopoulos, Meletios-Athanasios;
    • Schjesvold, Fredrik H.;
    • Hajek, Roman;
    • Abdulhaq, Haifaa;
    • Thuresson, Marcus;
    • Norin, Stefan;
    • Bakker, Nicolaas A.;
    • Mateos, Maria-Victoria
    Publication type:
    Article
    20

    OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S32, doi. 10.1016/S2152-2650(21)02124-8
    By:
    • Schjesvold, Fredrik;
    • Dimopoulos, Meletios-Athanasios;
    • Delimpasi, Sosana;
    • Robak, Pawef;
    • Coriu, Daniel;
    • Legiec, Wojciech;
    • Pour, Ludek;
    • Špicka, Ivan;
    • Masszi, Tamás;
    • Doronin, Vadim;
    • Minarik, Jiri;
    • Salogub, Galina;
    • Alexeeva, Yulia;
    • Lazzaro, Antonio;
    • Maisnar, Vladimir;
    • Mikala, Gábor;
    • Moody, Victoria;
    • Thuresson, Marcus;
    • Byrne, Catriona;
    • Harmenberg, Johan
    Publication type:
    Article
    21

    MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Blade, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    22

    MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
    By:
    • Richardson, Paul G;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemi;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    23

    Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
    By:
    • Richardson, Paul G.;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemí;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    24

    Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Bladé, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Factors associated with lung cancer in COPD patients.

    Published in:
    International Journal of COPD, 2018, v. 13, p. 1833, doi. 10.2147/COPD.S162484
    By:
    • Sandelin, Martin;
    • Mindus, Stéphanie;
    • Thuresson, Marcus;
    • Lisspers, Karin;
    • Ställberg, Björn;
    • Johansson, Gunnar;
    • Larsson, Kjell;
    • Janson, Christer
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 1983, doi. 10.1111/dom.13299
    By:
    • Kosiborod, Mikhail;
    • Birkeland, Kåre I.;
    • Cavender, Matthew A.;
    • Fu, Alex Z.;
    • Wilding, John P.;
    • Khunti, Kamlesh;
    • Holl, Reinhard W.;
    • Norhammar, Anna;
    • Jørgensen, Marit E.;
    • Wittbrodt, Eric T.;
    • Thuresson, Marcus;
    • Bodegård, Johan;
    • Hammar, Niklas;
    • Fenici, Peter;
    • the CVD‐REAL Investigators and Study Group
    Publication type:
    Article